USFDA issues 6 observations for Zydus Lifesciences Ahmedabad facility

Published On 2023-12-23 06:00 GMT   |   Update On 2023-12-26 15:42 GMT

Ahmedabad: Zydus Lifesciences has announced that the U.S. Food and Drug Administration (USFDA) has closed the inspection with 6 observations at the Company's API site situated at Changodar, Ahmedabad.This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023. "There were no Data Integrity related observations. There are no repeat observations from the...

Login or Register to read the full article

Ahmedabad: Zydus Lifesciences has announced that the U.S. Food and Drug Administration (USFDA) has closed the inspection with 6 observations at the Company's API site situated at Changodar, Ahmedabad.

This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023.
"There were no Data Integrity related observations. There are no repeat observations from the previous inspection. There are 4 DMFs of this site under approval with the USFDA. The Company will closely work with the USFDA to address the observations" the Company informed in a recent BSE filing.
Medical Dialogues team had earlier announced that the Company had received the Establishment Investigation Report (EIR) report from the USFDA for the injectables manufacturing facility at Zydus Biotech Park located at Changodar, Ahmedabad.

Read also: Zydus receives EIR for injectables manufacturing facility at Zydus Biotech Park, Ahmedabad

Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.

Read also: Zydus Lifesciences arm Zydus Noveltech dissolves

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News